Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Fabry Disease Market Growth in 2025?
In the past few years, the market size for Fabry disease has been witnessing significant growth. The market, which is projected to expand from $2.10 billion in 2024 to $2.28 billion in 2025, is expected to have a compound annual growth rate (CAGR) of 8.2%. This substantial rise during the historic period can be credited to factors like the surge in awareness and diagnosis of uncommon diseases, development in specialized healthcare facilities, government incentives and rare drug nominations, growth in funding for rare disease research, and the initial release of therapies.
What Is the Forecast for the Fabry Disease Market Size Through 2029?
The market size of Fabry disease is anticipated to experience strong expansion in the upcoming years, skyrocketing to $3.10 billion by 2029, with a compound annual growth rate (CAGR) of 8.0%. Factors contributing to this incline during the forecast period include the enlarging scope of newborn screening programs, legislative support for orphan and rare disease medication, increased accessibility of healthcare services, the surge of telemedicine and distance health care, and the escalating requirement for tailor-made medicine. Key trends during this period are the utilization of enzyme replacement therapy, advancements in genetic examination, incorporation of AI and digital mechanisms for preliminary detection, AI-driven diagnostic systems, and breakthroughs in gene therapy.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24218&type=smp
What are the Key Market Players in Fabry Disease Market and How They’re Evolving?
Major companies operating in the fabry disease market are Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, JCR Pharmaceuticals Co. Ltd., Sumitomo Pharma Co. Ltd, Chiesi Farmaceutici S.p.A., Amicus Therapeutics Inc., Idorsia Pharmaceuticals Ltd, Sangamo Therapeutics Inc., uniQure N.V., Protalix BioTherapeutics Inc., Spur Therapeutics Inc., Exegenesis Bio Inc., ISU ABXIS Co. Ltd., Eleva GmbH, AceLink Therapeutics Inc., 4D Molecular Therapeutics Inc., iBio Inc., Freeline Therapeutics Holdings plc, Greenovation Biotech GmbH
What Are the Primary Growth Drivers in the Fabry Disease Market?
The expansion of the Fabry disease market is projected to be fueled by an increased emphasis on personalized medicine. This approach of medical treatment considers a person’s genes, environment, and lifestyle to customize medical care and therapies specifically for them, leading to better outcomes. The surge in focus on personalized medicine is owing to its capacity to enhance treatment efficiency and curb side effects by adapting therapies to meet individual patient needs. Personalized medicine empowers the creation of treatment plans based on a patient’s unique genetic mutation and disease severity, elevating outcomes and reducing unnecessary side effects. For example, the U.S.-based non-profit organization, the Personalized Medicine Coalition, played a significant role. In 2023, the FDA granted approval for 16 new personalized treatments for those with rare diseases, a marked increase compared to the six approvals in 2022. Consequently, the burgeoning emphasis on personalized medicine underpins the growth of the fabry disease market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24218&type=smp
What Are the Leading Segments in the Global Fabry Disease Industry?
The fabry disease market covered in this report is segmented –
1) By Type: Type 1, Type 2, Other Types
2) By Treatment: Enzyme Replacement Therapy, Oral Therapy, Adjunct Therapy, Other Treatments
3) By Diagnosis: Blood Test, Genetic Test, Parenteral Test, Other Diagnosis
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegment:
1) By Type 1: Classic Fabry Disease, Later-Onset Fabry Disease
2) By Type 2: Cardiovascular-Focused Fabry Disease, Renal-Focused Fabry Disease
3) By Other Types: Variant Fabry Disease, X-linked Fabry Disease
What Are the Key Market Trends in the Fabry Disease Industry?
The focus of leading firms in the Fabry disease market is on the creation of novel therapies such as PEGylated enzyme replacement therapy (ERT) to improve efficacy of treatment, patient adherence, and minimize the immunogenic reactions in relation to traditional ERTs. PEGylated enzyme replacement therapy (ERT) is an advanced version of standard ERT, where polyethylene glycol (PEG) chains are combined with the enzyme to enhance its stability, extend its lifespan in the body, and reduce the immune system’s reactions. For instance, in May 2023, Chiesi Global Rare Diseases, a segment of the Italy-based Chiesi Group, disclosed that the U.S. Food and Drug Administration (FDA), a US government organization, gave approval for PRX-102 (pegunigalsidase alfa) for treating adult Fabry disease patients. This approval comes on the back of an intensive clinical program involving over 140 patients and long-term tracking for up to 7.5 years, revealing the effectiveness of the therapy in minimizing renal Gb3 deposits and preservation of kidney functionality while showcasing a promising safety profile.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/fabry-disease-global-market-report
What Is the Regional Outlook for the Fabry Disease Market?
North America was the largest region in the fabry disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/customise?id=24218&type=smp
This Report Delivers Insight On:
1. How big is the fabry disease market, and how is it changing globally?
2. Who are the major companies in the fabry disease market, and how are they performing?
3. What are the key opportunities and risks in the fabry disease market right now?
4. Which products or customer segments are growing the most in the fabry disease market?
5. What factors are helping or slowing down the growth of the fabry disease market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model